Colorectal Cancer Metastatic Clinical Trial
— COMBATACOfficial title:
Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.
Verified date | August 2018 |
Source | University of Regensburg |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from colorectal cancer.
Status | Terminated |
Enrollment | 26 |
Est. completion date | October 2017 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 71 Years |
Eligibility |
Inclusion Criteria: - Synchronous or metachronous peritoneal carcinomatosis arising from histologically proven colorectal or appendiceal adenocarcinoma - Complete macroscopic cytoreduction (CCR-0/1) - Free treatment interval of at least 6 month after the last chemotherapy - Age over 18 and below 71 years - Good general health status (Karnofsky > 70%, ECOG 0-2) - Absence of hematogenous metastasis (lung, bone, brain, > 3 peripheric resectable liver metastases) - Absence of contraindication for systemic chemotherapy and/or extended surgery - Life expectancy greater than 6 months - Written informed consent - Creatinine clearance > 50 ml/min, serum creatinine = 1.5 x ULN - Serum bilirubin = 1.5 x ULN (upper limit of normal), ASAT and ALAT = 2.5 x ULN - Platelet count > 100,000 /ml, haemoglobin > 9 g/dl, neutrophile granulocytes = 1,500 /ml, International Normalized Ration (INR) = 2 - Absence of peripheral neuropathy > grade 1 (CTCAE v4.0) - No pregnancy or breast feeding. Adequate contraception in fertile patients. Exclusion Criteria: - Incomplete cytoreduction - Hematogenous metastasis including irresectable liver metastasis - Prior chemotherapy or therapy with EGFR receptor antibody for metastatic disease - K-ras mutation - Known allergy to murine or chimeric monoclonal antibodies - Histology of signet ring carcinoma - Other malignancy than disease under study / second cancer - Impaired liver, renal or hematologic function as mentioned above (inclusion criteria) - Heart failure NYHA = 2 or significant Coronary Artery Disease - Alcohol and/or drug abuse - Patients unable or unwilling to comply with the study protocol, treatment or follow-up - Patients included in other clinical trials interfering with the present study |
Country | Name | City | State |
---|---|---|---|
Germany | Charité Campus Mitte, Humboldt-University Berlin | Berlin | |
Germany | Medical Center of the Friedrich-Alexander-University Erlangen- Nürnberg | Erlangen | |
Germany | Cologne-Merheim Medical Center, University Witten/Herdecke | Koeln | |
Germany | St. John of God Hospital Regensburg | Regensburg | |
Germany | University Hospital Regensburg | Regensburg | |
Germany | University Hospital, University of Tuebingen | Tuebingen | |
Germany | University Hospital Wuerzburg, Julius-Maximilians University | Wuerzburg |
Lead Sponsor | Collaborator |
---|---|
University of Regensburg | Heinrich-Heine University, Duesseldorf |
Germany,
Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer. 2013 Feb 7;13:67. doi: 10.1186/1471-2407-13-67. — View Citation
Glockzin G, Zeman F, Croner RS, Königsrainer A, Pelz J, Ströhlein MA, Rau B, Arnold D, Koller M, Schlitt HJ, Piso P. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peri — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | 24 months | ||
Secondary | Overall survival (OS) | 5 years | ||
Secondary | Feasibility of the combined treatment concept | Assessment of tumor progression, AE and SAE during treatment phase leading to modification or end of treatment. | 9 months | |
Secondary | Quality of life (QoL) | assessed by EORTC-QLQ-C30 | 2 years | |
Secondary | Pathohistological regression | assessed by Dworak grade of regression in histology after surgery | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03941080 -
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Completed |
NCT03647839 -
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Terminated |
NCT02316496 -
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
|
Phase 2 | |
Completed |
NCT03251612 -
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02380443 -
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02149784 -
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT01959061 -
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
|
Phase 4 | |
Terminated |
NCT01668680 -
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05068531 -
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
|
||
Not yet recruiting |
NCT04525807 -
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
|
||
Completed |
NCT04482608 -
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
|
||
Recruiting |
NCT03193710 -
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
|
N/A | |
Recruiting |
NCT04854213 -
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 | |
Completed |
NCT03144804 -
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01910610 -
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05759728 -
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |